• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy.接受美泊利珠单抗治疗的患者感染严重急性呼吸综合征冠状病毒2
Ann Allergy Asthma Immunol. 2021 Apr;126(4):438-440. doi: 10.1016/j.anai.2021.01.006. Epub 2021 Jan 13.
2
Mepolizumab in the treatment of severe eosinophilic asthma.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘。
Immunotherapy. 2016;8(1):27-34. doi: 10.2217/imt.15.102. Epub 2015 Dec 10.
3
Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘：一位临床医生的治疗结果
Ann Allergy Asthma Immunol. 2018 Jul;121(1):121-123. doi: 10.1016/j.anai.2018.04.016. Epub 2018 Apr 21.
4
Mepolizumab-based therapy in asthma: an update.基于美泊利珠单抗的哮喘治疗：最新进展
Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):392-6. doi: 10.1097/ACI.0000000000000183.
5
Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.抗白细胞介素-5单克隆抗体美泊利珠单抗治疗嗜酸性粒细胞性中耳炎的临床疗效
Auris Nasus Larynx. 2019 Apr;46(2):196-203. doi: 10.1016/j.anl.2018.07.011. Epub 2018 Aug 16.
6
Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study.美泊利单抗治疗重度嗜酸性粒细胞性哮喘上下气道的临床疗效良好：一项48周的前瞻性研究。
Eur Ann Allergy Clin Immunol. 2019 Sep 16;51(5):213-221. doi: 10.23822/EurAnnACI.1764-1489.94. Epub 2019 Apr 15.
7
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.评估美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘的长期安全性和临床应答的持久性。
J Allergy Clin Immunol. 2019 May;143(5):1742-1751.e7. doi: 10.1016/j.jaci.2018.09.033. Epub 2018 Oct 23.
8
Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.抗白细胞介素-5 治疗轻度哮喘对鼻病毒诱导的巨噬细胞、B 细胞和中性粒细胞反应的影响（材料）。一项安慰剂对照、双盲研究。
Am J Respir Crit Care Med. 2019 Feb 15;199(4):508-517. doi: 10.1164/rccm.201803-0461OC.
9
Mepolizumab use: Post-approval academic practice experience.美泊利单抗的使用：批准后学术实践经验
Ann Allergy Asthma Immunol. 2018 Jul;121(1):126-128. doi: 10.1016/j.anai.2018.04.001. Epub 2018 Apr 10.
10
Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.血液嗜酸性粒细胞计数是一种有用的生物标志物，可用于识别患有严重嗜酸性粒细胞性哮喘的患者。
Ann Am Thorac Soc. 2014 May;11(4):531-6. doi: 10.1513/AnnalsATS.201310-354OC.

引用本文的文献

1
Long-term alveolar-capillary diffusion impairments after severe SARS-CoV-2 pneumonia.严重新型冠状病毒肺炎后的长期肺泡-毛细血管扩散功能障碍
Ann Med. 2025 Dec;57(1):2483383. doi: 10.1080/07853890.2025.2483383. Epub 2025 Mar 28.
2
Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics.重症哮喘与活动性SARS-CoV-2感染：生物制剂的见解
Biomedicines. 2025 Mar 10;13(3):674. doi: 10.3390/biomedicines13030674.
3
Immune responses in children with secondary infection of mycoplasma pneumoniae after COVID-19: focus on eosinophils and IgE.新冠病毒感染后支原体肺炎继发感染儿童的免疫反应：聚焦嗜酸性粒细胞和免疫球蛋白E
BMC Infect Dis. 2025 Jan 28;25(1):134. doi: 10.1186/s12879-025-10534-0.
4
Treatment of Severe Asthma: Case Report of Fast Action of Mepolizumab in a Patient with Recent SARS-CoV-2 Infection.重症哮喘的治疗：美泊利珠单抗对近期感染新型冠状病毒2的患者快速起效的病例报告
Life (Basel). 2024 Aug 25;14(9):1063. doi: 10.3390/life14091063.
5
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.美泊利单抗治疗重度哮喘3年的长期疗效：与临床试验及超级应答者的比较
Biomedicines. 2023 Aug 30;11(9):2424. doi: 10.3390/biomedicines11092424.
6
Repurposing of Chemotherapeutics to Combat COVID-19.化疗药物用于抗击新型冠状病毒肺炎的新用途
Curr Top Med Chem. 2022;22(32):2660-2694. doi: 10.2174/1568026623666221130142517.
7
SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.严重哮喘患者接受生物制剂治疗后感染 SARS-CoV-2。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2588-2595. doi: 10.1016/j.jaip.2022.05.041. Epub 2022 Jun 23.
8
COVID-19  vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.COVID-19 疫苗接种在接受过敏原免疫治疗（AIT）或生物制剂治疗的患者中的应用——EAACI 建议。
Allergy. 2022 Aug;77(8):2313-2336. doi: 10.1111/all.15252. Epub 2022 Mar 18.
9
Eosinophils and eosinophilic immune dysfunction in health and disease.在健康和疾病中嗜酸性粒细胞和嗜酸性免疫功能障碍。
Eur Respir Rev. 2022 Jan 25;31(163). doi: 10.1183/16000617.0150-2021. Print 2022 Mar 31.
10
Understanding and Managing Severe Asthma in the Context of COVID-19.在2019冠状病毒病背景下理解和管理重度哮喘
Immunotargets Ther. 2021 Dec 11;10:419-430. doi: 10.2147/ITT.S342636. eCollection 2021.

本文引用的文献

1
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI).在当前新冠疫情期间生物制剂在过敏性和2型炎症性疾病中的应用：德国过敏症专科医生协会（AeDA）、德国过敏与临床免疫学会（DGAKI）、儿科过敏与环境医学学会（GPA）、奥地利过敏与免疫学会（ÖGAI）、卢森堡过敏与免疫学会（LGAI）、奥地利肺病学会（ÖGP）与德国、奥地利和瑞士的ARIA小组以及欧洲变态反应和临床免疫学会（EAACI）合作发布的立场文件
Allergol Select. 2020 Sep 7;4:53-68. doi: 10.5414/ALX02166E. eCollection 2020.
2
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).ARIA-EAACI关于哮喘与2019冠状病毒病的声明（2020年6月2日）
Allergy. 2021 Mar;76(3):689-697. doi: 10.1111/all.14471. Epub 2020 Sep 21.
3
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.使用 ISARIC WHO 临床特征协议住院的 20133 例英国新冠患者的特征：前瞻性观察队列研究。
BMJ. 2020 May 22;369:m1985. doi: 10.1136/bmj.m1985.
4
Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study.嗜酸性粒细胞减少和C反应蛋白升高有助于发热门诊对COVID-19患者进行分诊：一项回顾性病例对照研究。
EClinicalMedicine. 2020 May 3;23:100375. doi: 10.1016/j.eclinm.2020.100375. eCollection 2020 Jun.
5
Eosinophil responses during COVID-19 infections and coronavirus vaccination.COVID-19 感染和冠状病毒疫苗接种期间的嗜酸性粒细胞反应。
J Allergy Clin Immunol. 2020 Jul;146(1):1-7. doi: 10.1016/j.jaci.2020.04.021. Epub 2020 Apr 25.
6
COVID-19 Autopsies, Oklahoma, USA.美国俄克拉荷马州的 COVID-19 尸检。
Am J Clin Pathol. 2020 May 5;153(6):725-733. doi: 10.1093/ajcp/aqaa062.
7
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study.85 例武汉 COVID-19 死亡病例的临床特征。一项回顾性观察研究。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379. doi: 10.1164/rccm.202003-0543OC.
8
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
9
Blood eosinophil count in the general population: typical values and potential confounders.一般人群中的血嗜酸性粒细胞计数：典型值和潜在混杂因素。
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.01874-2019. Print 2020 May.
10
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.

Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy.

作者信息

Azim Adnan, Pini Laura, Khakwani Zeeshan, Kumar Santosh, Howarth Peter

机构信息

Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Southampton Biomedical Research Centre, National Institute for Health Research, University Hospital Southampton National Health Service Foundation Trust, Southampton, United Kingdom.

Respiratory Medicine Unit, Spedali Civili, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

出版信息

Ann Allergy Asthma Immunol. 2021 Apr;126(4):438-440. doi: 10.1016/j.anai.2021.01.006. Epub 2021 Jan 13.

DOI:10.1016/j.anai.2021.01.006
PMID:33453381
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7804376/
Abstract
摘要